I think smart investors should buy these ASX 200 blue-chip shares with $10,000

Unsure where to invest $10,000? I think putting the funds into blue-chip ASX 200 shares could be a smart move.

But which ones?

Three that I rate as buys for smart investors are named below.

Qantas Airways Ltd (ASX: QAN)

Airlines aren’t usually thought of as long-term growth plays, but Qantas is far from typical. I like the way it’s reinvesting earnings into the fleet, which is driving efficiency, lowering maintenance costs, and opening up new long-range routes.

The airline delivered 9 new aircraft during the first half and is accelerating deliveries, with 30 more expected over the next 18 months.

That matters because capital-intensive industries like airlines often separate winners from average operators through asset quality and operational flexibility. Qantas’ newer aircraft are cheaper to run and allow it to compete more effectively domestically and internationally.

The company also operates in a relatively rational market. Alongside Virgin Australia Holdings Ltd (ASX: VGN), Qantas benefits from a duopoly that supports healthier margins than in oversaturated global markets.

Domestic operations delivered $1.05 billion in underlying EBIT in the first half, up 14%, while its Loyalty division contributed $286 million, up 12%. Combined with the strong-performing Jetstar business, these give Qantas a strong foundation for sustainable profits.

Recent share price weakness has been influenced by surging oil prices, which are now around US$100 per barrel amid conflict in the Middle East. But I see this pullback as an opportunity rather than a red flag.

Wesfarmers Ltd (ASX: WES)

Wesfarmers is my quality pick. It’s a diversified industrial group with solid operations across Bunnings, Kmart, WesCEF, and other subsidiaries. Its half-year results last month showed profit growth of over 9%, supported by strong sales and productivity improvements.

Bunnings continues to perform well despite subdued residential construction, and Kmart’s everyday low-price model gives it a structural advantage. Meanwhile, WesCEF’s lithium contribution is increasingly relevant as energy markets shift toward electrification.

I like businesses that can grow profit across different economic conditions, and Wesfarmers does exactly that.

For a $10,000 investment, it offers a combination of stability, quality, and optionality that complements more cyclical or high-growth investments.

ResMed Inc (ASX: RMD)

ResMed is a standout ASX 200 blue-chip share in healthcare. The medical device company addresses obstructive sleep apnoea, a condition affecting over a billion people globally, yet remains underpenetrated in many regions. That structural tailwind is enormous and long term.

Financially, ResMed is strong. Revenue for the December quarter hit US$1.4 billion, up 11% year on year, with gross margins expanding to 61.8%, and operating income up 18%.

The balance sheet is healthy, with US$715 million in net cash, providing flexibility for R&D, acquisitions, dividends, and buybacks.

What sets ResMed apart for me is its ecosystem approach. It’s not just a device maker, it’s a connected health platform. With tens of millions of patients linked to its cloud systems, ResMed benefits from data-driven network effects and switching costs.

Furthermore, innovation continues with new product rollouts and AI-enabled features like Smart Comfort, further strengthening the company’s competitive moat.

Foolish Takeaway

With $10,000 to invest, I’d spread it across these three ASX 200 blue-chip shares to balance quality, growth, and structural advantages. 

Qantas offers cyclical exposure with a strong domestic franchise and long-term fleet upgrades. Wesfarmers provides stability, dividends, and optionality across diverse industrial businesses. ResMed gives exposure to a high-margin, underpenetrated global healthcare opportunity with structural tailwinds.

The post I think smart investors should buy these ASX 200 blue-chip shares with $10,000 appeared first on The Motley Fool Australia.

More reading

• 2 amazing ASX shares to buy for long-term growth
• Qantas shares extend losses as fuel costs reshape operations
• Why Qantas shares could be flying into turbulence
• 3 top Vanguard ETFs I would buy in April
• What could $500 a month in ASX 200 shares become in 20 years?

Motley Fool contributor Grace Alvino has positions in Wesfarmers. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed and Wesfarmers. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.